Press Releases

Numinus Completes Acquisition of Neurology Centre of Toronto

Acquisition strengthens clinic portfolio for mental health treatment using psychedelic-assisted ther

Numinus to Participate in Upcoming Investor Conferences in September 2021

VANCOUVER, BC, September 2, 2021 — Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI)

Woman with dark, curly hair, staring at the lake with the sunlight reflected off the water in front of her

Numinus Wellness Closes Q3 2021 With $63.2 Million Cash Position, Lab and Trial Advances, and Strategic Expansion into Psychedelic Neurology

VANCOUVER, BC, July 29, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a

Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD

Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disor

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology

NCT’s treatment of neurological disorders combined with Numinus’ leadership in psychedelic-assis

Dark skinned young man sitting with his back against the wall and his hand resting against his forehead with his eyes closed

Numinus Announces Update to Escrow Release Schedule

VANCOUVER, BC, June 25, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV:

Interior of a forest with dense trees and large rocks

Numinus Announces Grant of Stock Options

VANCOUVER, BC, June 24, 2021 – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV:

Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective a

Numinus Wellness Graduates to Tier 1 on the TSX Venture Exchange

VANCOUVER, BC, June 18, 2021 - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a

FR: Numinus Wellness annonce le recrutement de dirigeants clés pour soutenir sa croissance rapide et l’innovation

Des gestionnaires chevronnés pourvoient des postes de direction dans le développement des affaires

Numinus Wellness Announces Key Leadership Hires to Support Rapid Growth and Innovation

Cliquez ici pour la version française Experienced executives fill senior roles in business devel

FR: Numinus Wellness et Optimi Health soumettent un extrait de psilocybine entièrement naturelle à Santé Canada en vue d’une demande d’essai pré-clinique

Le partenariat vise à offrir des capsules psychédéliques pour une étude posologique dans un ess

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Cliquez ici pour la version française Partnership Aimed at Delivering Psychedelic Capsule for D

FR: Numinus félicite MAPS pour son essai clinique de phase 3 révélant des bienfaits significatifs de la thérapie assistée par MDMA dans le traitement du SSPT grave

Une collaboration entre Numinus et l’Association multidisciplinaire pour les études psychédéliq

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits of MDMA-Assisted Therapy for Severe PTSD

Cliquez ici pour la version française Numinus and Multidisciplinary Association for Psychedelic

Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC

Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial VANC

FR: Numinus annonce un essai clinique de phase 1 sur l’extraction naturelle de champignons psilocybe préparée au laboratoire de la société

L’essai clinique évaluera la sécurité et les propriétés psychoactives de la psilocybine natur

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction Prepared at Company Lab

Cliquez ici pour la version française Clinical trial will evaluate safety and psychoactive prope

Numinus Announces Listing of Warrants and Change of Trading Symbol for Previously Listed Warrants

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Van

FR: Numinus annonce la clôture d’un financement par voie de prise ferme de 40 M$

LE PRÉSENT COMMUNIQUÉ DE PRESSE EST DESTINÉ À ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT ET N’EST PAS

Numinus Announces Closing of $40-Million Bought Deal Financing

Cliquez ici pour la version française THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA O

FR: Numinus Wellness Inc. annonce un placement public de 30 M$ par voie de prise ferme

LE PRÉSENT COMMUNIQUÉ DE PRESSE EST DESTINÉ À ÊTRE DIFFUSÉ AU CANADA UNIQUEMENT ET N'EST PAS D

Numinus Wellness Inc. Announces Upsized Bought Deal Public Offering to $35 Million

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION T

Numinus Wellness Inc. Announces $30 Million Bought Deal Public Offering

Cliquez ici pour la version française THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA O

FR: Numinus agrandira son laboratoire de recherche ultramoderne sur les psychédéliques

Numinus Bioscience ajoutera un espace de recherche, améliorera les services contractuels, accélè

Numinus to expand state-of-the-art psychedelics research laboratory

Cliquez ici pour la version française Numinus Bioscience adds research space, enhances contract

FR: Les laboratoires Numinus au premier plan de la recherche mondiale sur les psychédéliques suite aux autorisations réglementaires

Numinus Bioscience ajoute à sa licence la kétamine et le LSD pour produire, assembler et vendre un

Regulatory Approvals Place Numinus Lab at the Forefront of Global Psychedelics Research

Cliquez ici pour la version française Numinus Bioscience adds Ketamine and LSD to licence to produ

FR: Numinus et Syreon fournissent une mise à jour concernant les essais cliniques à accès compassionnel sur la psilocybine

Des progrès significatifs ont été réalisés, alors que l’étude PRIME, parrainée par Numinus,

Numinus and Syreon Provide Psilocybin Compassionate Access Trial Update

Cliquez ici pour la version française Significant progress made as Numinus-sponsored PRIME study

FR: Numinus annonce des avancées dans les essais cliniques à accès compassionnel pour la thérapie assistée par MDMA en collaboration avec MAPS Public Benefit Corporation

Les essais cliniques entrent en phase préparatoire après avoir franchi plusieurs jalons importants

Numinus announces milestones in compassionate access trial for MDMA-assisted therapy in collaboration with MAPS Public Benefit Corporation

Cliquez ici pour la version française Trial enters pre-implementation stage having met several k

FR: Numinus Wellness finalise l’acquisition de Mindspace Wellbeing, basée à Montréal

Cette acquisition renforce la présence de Numinus tout en améliorant le paysage des thérapies ass

Numinus Wellness Completes Acquisition of Montreal-based Mindspace Wellbeing

Cliquez ici pour la version française Acquisition expands Numinus’ presence while improving ps

Numinus Engages Native Ads Inc. for Digital Media Services

VANCOUVER (February 5, 2021) – Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI),

Numinus Wellness Closes Q1 2021 with Strong Cash Position and Industry Firsts

Key milestones met in ongoing trials , expanding national footprint, and enhanced research capabili

FR: Numinus Wellness fait avancer la recherche axée sur la découverte en matière de psychédéliques grâce au spectromètre de masse Orbitrap Exploris 120

L’acquisition de cet instrument de pointe de Thermo Fisher Scientific fera grandement progresser l

Numinus Wellness Forges Forward into Psychedelic Discovery Research with the Orbitrap Exploris 120 Mass Spectometer

Cliquez ici pour la version française Acquisition of industry-leading instrument by Thermo Fishe

FR: Numinus et Optimi Health signent une entente de services de laboratoire pour faire progresser la recherche et le développement de produits psychédéliques

L’entente sera axée sur la mise au point de produits sûrs, efficaces et entièrement naturels po

Numinus Signs Lab Services Agreement with Optimi Health to Advance Research and Development of Psychedelic Products

Cliquez ici pour la version française The agreement will focus on developing safe, effective, al

Numinus Announces Closing of $17 Million Bought Deal Offering Including Full Exercise of Over-Allotment Option

Proceeds add to recently executed warrants and options of $8.9 million NOT FOR DISTRIBUTION TO UN

FR: Une clinique montréalaise offre des thérapies assistées à la kétamine

99La substance est déjà largement utilisée dans le système de santé comme anesthésique et anti

Numinus Completes First Extraction of its Psilocybe Mushrooms

Canada’s first legal extraction by a public company is a landmark moment for the global psychedeli

FR: Numinus Wellness annonce son expansion nationale avec l’acquisition de Mindspace Wellbeing, un organisme de bien-être à services complets basé à Montréal et pionnier en matière de thérapies psychédéliques

Cette association renforce la position de Numinus en tant que chef de file dans le domaine de la psy

Numinus Wellness Announces National Expansion with Acquisition of Montreal-Based Mindspace Wellbeing, a Full-service Well-being Organization and Pioneer in Psychedelic Programming

Cliquez ici pour la version française The combination further enhances Numinus’ leadership pos

Numinus Wellness commends Health Canada for its intent to make MDMA and psilocybin treatment available through the Special Access Programme

First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in

Numinus Wellness Inc. Announces an Increase to the Previously Announced Bought Deal Public Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION T

Numinus Wellness Inc. Announces $10 Million Bought Deal Public Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED

Numinus and MAPS to Collaborate on MDMA Trial for PTSD

Vancouver-based firm Numinus announced yesterday it will collaborate with an arm of a longstanding n

“Buried by Puppies Licking Your Face” (Canadian Firms Champion MDMA for PTSD)

Numinus Wellness Inc. and Multidisciplinary Association for Psychedelic Studies Public Benefit Cor

Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support

New Magic Mushroom Clinical Trial to Treat Addiction

Could magic mushrooms treat addiction? Vancouver based company Numinus has announced a new clinic

Vancouver company announces clinical trial of psilocybin-assisted psychotherapy for substance use disorders

Vancouver-based Numinus Wellness Inc. has announced a 30-person clinical trial to establish the best

Down (the Rabbit Hole) and Out (of Addiction)

Magic Mushrooms, now legal in Oregon. have shown promise in treatment of addiction and depression.

Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders

Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-ass

Numinus Becomes The First Canadian Psychedelics Company To Legally Harvest Magic Mushrooms

Numinus CEO Payton Nyquvest and COO Michael Tan sat down with Forbes to discuss the company's harves

Vancouver company completes first legal harvest of psilocybe mushrooms

Vancouver-based Numinus Wellness Inc. has completed its first harvest of psilocybe mushrooms, said t

Numinus Announces First Legal Harvest of Psilocybe Mushrooms

Vancouver-based health care company Numinus Bioscience has officially harvested the first legal ba

Numinus First Canadian Public Company to Complete Legal Harvest of Psilocybe Mushrooms

Numinus Bioscience's developments include harvesting its first flush of Psilocybe mushrooms at i

Numinus Appoints Multidisciplinary Global Leaders to its General Advisory Council

Advisors, including human performance expert Jamie Wheal and mental health advocate Ben Nemtin, join

Numinus Commences Psilocybe Mushroom Cultivation at its Health Canada Licensed Laboratory

Numinus progresses on its ecosystem approach to the ultimate delivery of safe, evidence-based, acces

Numinus Announces Listing of Warrants

VANCOUVER, BC, Sept. 18, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUM

Numinus Announces Closing of Oversubscribed $4.6 Million Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Van

Numinus Announces Filing of Final Short Form Prospectus for Offering of up to $4,000,000

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of

Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness

Numinus provides tailored treatments for clients of one of Canada's largest addiction treatment orga

Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4,050,000

VANCOUVER, BC, July 28, 2020 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI

Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 Million

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a company creating an ecosystem of

Numinus announces Clinical Advisory Council to advance integrated wellness model

Advisors including Dr. Gabor Maté and Zach Walsh bring training and expertise in psychedelic-assist

Numinus licensed by Health Canada to extract and research psilocybin

Numinus CEO, Payton Nyquvest, and Chief Operating Officer, Michael Tan, spoke to Mugglehead about an

Numinus Licencing Amendment: We Speak to the Team

Numinus Chief Operating Officer Michael Tan explains what the company's recent Health Canada licence

Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms

Numinus becomes first publicly traded company in Canada approved to conduct research of this kind u

Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director

Medical doctor experienced in psychedelic assisted therapy and research to help advance Numinus

Numinus Announces 2020 Operational Plans to Scale

Company gives guidance on near-term business objectives VANCOUVER (May 28th, 2020)— Numinus Wel

Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council

Maté will collaborate with the Numinus team in an advisory capacity and facilitate connections wi

Canada could regulate psychedelic therapy within few years, bets company

Numinus Wellness outlines where they see the business and the industry going following their public

Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer

Wood will lead research partnerships and the design of the Numinus patient-focused mod

Numinus Wellness Inc. commences trading on TSX Venture Exchange as NUMI

Integrated company to play a lead role in emerging psychedelic assisted therapy and research space

Numinus Wellness Inc. (formerly Rojo Resources Ltd.) closes RTO with Salvation Botanicals LTD; to commence trading under “NUMI”

Numinus Wellness Inc. (formerly Rojo Resources Ltd., RJ:H) (“Numinus” or the “Company”) (TSX

Rojo Resources Ltd. announces the conditional approval of reverse take-over transaction with Salvation Botanicals Ltd.

Rojo Resources Ltd. (“Rojo” or the “Company”) (TSXV: RJ:H) is pleased to announce that it ha

Rojo Resources Ltd. announces closing of subscription receipt offering, Salvation Botanicals closes sidecar private placement – aggregate gross proceeds of $6,000,000 raised

VANCOUVER (March 10, 2020) — Rojo Resources Ltd. (“Rojo” or the “Company”) (TSXV: RJ:H) is

End-to-end solution in psychedelic therapies establishes Numinus as leader in emerging space

VANCOUVER (February 24, 2020)—With momentum building for the use of psychedelic substances in the